Skip to main content
NIH funding notice PAR-16-171

Innovation for HIV Vaccine Discovery (R01)

Closed on August 1, 2016.

Posted
April 7, 2016
Close date
August 1, 2016
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,411,744 in first-year total cost, median $705,872.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 AARR-P (51)]2

Most frequent institutions

  1. UNIVERSITY OF PENNSYLVANIA1
  2. UNIVERSITY OF WASHINGTON1
Competing awards under PAR-16-171 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2017bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs1R01AI131331-01SHAW, GEORGE MUNIVERSITY OF PENNSYLVANIA, PA$796,855ZRG1
2017VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION1R01AI131403-01HU, SHIU-LOKUNIVERSITY OF WASHINGTON, WA$614,889ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-16-171: Innovation for HIV Vaccine Discovery (R01) | ScienceDex | ConductScience